Hormonal treatment options include: Combined oral contraceptives : Continuous or cyclic regimens can reduce menstrual flow and suppress endometrial tissue activity Progestins : Available as oral medications, injections (depot medroxyprogesterone acetate), intrauterine devices (levonorgestrel-releasing IUD), or implants GnRH agonists : These medications induce a temporary menopausal state, effectively suppressing endometriosis but requiring add-back hormone therapy to minimize bone loss and vasomotor symptoms GnRH antagonists : FDA-approved oral options include elagolix (Orilissa) and relugolix/estradiol/norethindrone (Myfembree) with specific duration limits based on dosing and bone health considerations Aromatase inhibitors : Sometimes used in refractory cases, though not FDA-approved for this indication Bone mineral density monitoring is recommended for patients on long-term GnRH agonists or antagonists, particularly at higher doses or extended durations
Translational opportunities in animal and human models to study alcohol use disorder
children aged 12 years old are exposed to second hand smoking in their homes, and 38% suffer from 1 or more neurobehavioral disorders
Although some therapeutic benefits appear to exhibit more statistical significance than clinical meaning, the seemingly tiny improvement in these trials is capable of being replicated
The two statistical models were then combined to yield a data fusion block-scaling model from which several dozen molecules of interest were determined
